Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PRV

- PMLiVE

Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation

Provides hope for new treatment of rare cancer

- PMLiVE

NHS leaders warn of no-deal Brexit flu vaccine delays

Follows prior delay in production of the vaccine

- PMLiVE

Finch Therapeutics bags $53m for microbiome therapies

In race to be first-to-market in C diff

- PMLiVE

BeiGene gets speedy US review for lymphoma drug zanubrutinib

First US filing is major milestone for Chinese firm

- PMLiVE

Sanofi patent case win holds off generic rivals for key cancer drug

Boosts hope of increasing future sales

Novartis day

Senators attack Novartis over ‘unconscionable’ handling of Zolgensma data

Ask FDA to hold the company ‘accountable’

- PMLiVE

ICER closely monitoring FDA’s Zolgensma investigation

Could affect initial cost assessment

- PMLiVE

DBV refiles peanut allergy immunotherapy in the US

Follows initial manufacturing concerns

Novartis day

Novartis defends Zolgensma as FDA investigates ‘data manipulation’

Gene therapy will remain on the market

Bayer symbol

Bayer bags FDA nod for early prostate cancer drug darolutamide

new competition in the market

- PMLiVE

The fight for affordable insulin

Activists are organised, and demanding action on US insulin prices - and pointing the finger at pharma

- PMLiVE

Dupixent drives Sanofi again, but other new drugs are lagging

Reported loss due to restructuring

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links